Cantor analyst Josh Schimmer and JP Morgan analyst Eric Joseph initiated coverage on biopharma company Septerna (SEPN) with an Overweight rating. Schimmer highlights SEPN's innovative GPCR-targeting platform and lead asset, SEP-786, targeting hypoparathyroidism.